JP6698844B2 - いくつかの直径の細孔を含む再構築された組織のための膜 - Google Patents
いくつかの直径の細孔を含む再構築された組織のための膜 Download PDFInfo
- Publication number
- JP6698844B2 JP6698844B2 JP2018531519A JP2018531519A JP6698844B2 JP 6698844 B2 JP6698844 B2 JP 6698844B2 JP 2018531519 A JP2018531519 A JP 2018531519A JP 2018531519 A JP2018531519 A JP 2018531519A JP 6698844 B2 JP6698844 B2 JP 6698844B2
- Authority
- JP
- Japan
- Prior art keywords
- membrane
- pores
- tissue
- cell
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000012528 membrane Substances 0.000 title claims description 182
- 239000011148 porous material Substances 0.000 title claims description 131
- 210000004027 cell Anatomy 0.000 claims description 100
- 238000004113 cell culture Methods 0.000 claims description 39
- 238000000034 method Methods 0.000 claims description 25
- 239000002356 single layer Substances 0.000 claims description 19
- 238000004519 manufacturing process Methods 0.000 claims description 14
- 238000010899 nucleation Methods 0.000 claims description 13
- 238000013508 migration Methods 0.000 claims description 11
- 239000003795 chemical substances by application Substances 0.000 claims description 7
- 230000028709 inflammatory response Effects 0.000 claims description 7
- 238000012216 screening Methods 0.000 claims description 7
- 210000001640 nerve ending Anatomy 0.000 claims description 6
- 238000000338 in vitro Methods 0.000 claims description 5
- 230000004044 response Effects 0.000 claims description 5
- 230000001953 sensory effect Effects 0.000 claims description 5
- 230000012292 cell migration Effects 0.000 claims description 4
- 238000002360 preparation method Methods 0.000 claims description 4
- 230000001413 cellular effect Effects 0.000 claims description 3
- 229940079593 drug Drugs 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 3
- 230000005931 immune cell recruitment Effects 0.000 claims description 3
- 230000008520 organization Effects 0.000 claims description 3
- 229920006289 polycarbonate film Polymers 0.000 claims description 3
- 210000001519 tissue Anatomy 0.000 description 66
- 210000002569 neuron Anatomy 0.000 description 15
- 210000002865 immune cell Anatomy 0.000 description 14
- 210000000981 epithelium Anatomy 0.000 description 12
- 230000008569 process Effects 0.000 description 11
- 230000001086 cytosolic effect Effects 0.000 description 10
- 210000002919 epithelial cell Anatomy 0.000 description 10
- 238000005553 drilling Methods 0.000 description 8
- 210000001821 langerhans cell Anatomy 0.000 description 8
- 230000005012 migration Effects 0.000 description 8
- 239000011248 coating agent Substances 0.000 description 7
- 238000000576 coating method Methods 0.000 description 7
- -1 polyethylene Polymers 0.000 description 7
- 238000013334 tissue model Methods 0.000 description 7
- 210000004698 lymphocyte Anatomy 0.000 description 6
- 239000002609 medium Substances 0.000 description 6
- 229920000515 polycarbonate Polymers 0.000 description 6
- 239000004417 polycarbonate Substances 0.000 description 6
- 210000002615 epidermis Anatomy 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 4
- 230000004913 activation Effects 0.000 description 4
- 210000002510 keratinocyte Anatomy 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 229920000139 polyethylene terephthalate Polymers 0.000 description 4
- 239000005020 polyethylene terephthalate Substances 0.000 description 4
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 3
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 3
- 210000004443 dendritic cell Anatomy 0.000 description 3
- 238000009792 diffusion process Methods 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 210000002744 extracellular matrix Anatomy 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 230000002757 inflammatory effect Effects 0.000 description 3
- 239000010410 layer Substances 0.000 description 3
- 210000000265 leukocyte Anatomy 0.000 description 3
- 210000002540 macrophage Anatomy 0.000 description 3
- 210000001616 monocyte Anatomy 0.000 description 3
- 239000002243 precursor Substances 0.000 description 3
- 210000003491 skin Anatomy 0.000 description 3
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- SUHOOTKUPISOBE-UHFFFAOYSA-N O-phosphoethanolamine Chemical compound NCCOP(O)(O)=O SUHOOTKUPISOBE-UHFFFAOYSA-N 0.000 description 2
- 239000004698 Polyethylene Substances 0.000 description 2
- 239000004743 Polypropylene Substances 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 210000001130 astrocyte Anatomy 0.000 description 2
- 230000021164 cell adhesion Effects 0.000 description 2
- 210000005056 cell body Anatomy 0.000 description 2
- 230000003833 cell viability Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 210000002752 melanocyte Anatomy 0.000 description 2
- 230000000877 morphologic effect Effects 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 229920000728 polyester Polymers 0.000 description 2
- 229920000573 polyethylene Polymers 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 229920001155 polypropylene Polymers 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 208000017520 skin disease Diseases 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- QDZOEBFLNHCSSF-PFFBOGFISA-N (2S)-2-[[(2R)-2-[[(2S)-1-[(2S)-6-amino-2-[[(2S)-1-[(2R)-2-amino-5-carbamimidamidopentanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-N-[(2R)-1-[[(2S)-1-[[(2R)-1-[[(2S)-1-[[(2S)-1-amino-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]pentanediamide Chemical compound C([C@@H](C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(N)=O)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](N)CCCNC(N)=N)C1=CC=CC=C1 QDZOEBFLNHCSSF-PFFBOGFISA-N 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- 206010048768 Dermatosis Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000016359 Fibronectins Human genes 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 239000007760 Iscove's Modified Dulbecco's Medium Substances 0.000 description 1
- 102000007547 Laminin Human genes 0.000 description 1
- 108010085895 Laminin Proteins 0.000 description 1
- 108010039918 Polylysine Proteins 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- 102400000096 Substance P Human genes 0.000 description 1
- 101800003906 Substance P Proteins 0.000 description 1
- 102000004338 Transferrin Human genes 0.000 description 1
- 108090000901 Transferrin Proteins 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 239000007640 basal medium Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 210000003850 cellular structure Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 210000003040 circulating cell Anatomy 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 210000004087 cornea Anatomy 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 210000001787 dendrite Anatomy 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 210000001339 epidermal cell Anatomy 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 210000005003 heart tissue Anatomy 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000037456 inflammatory mechanism Effects 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000005228 liver tissue Anatomy 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000013028 medium composition Substances 0.000 description 1
- 238000010232 migration assay Methods 0.000 description 1
- 238000004264 monolayer culture Methods 0.000 description 1
- 210000002161 motor neuron Anatomy 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000000944 nerve tissue Anatomy 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 210000003061 neural cell Anatomy 0.000 description 1
- 210000002241 neurite Anatomy 0.000 description 1
- 210000004498 neuroglial cell Anatomy 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 210000004248 oligodendroglia Anatomy 0.000 description 1
- 238000000879 optical micrograph Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 229920000656 polylysine Polymers 0.000 description 1
- 108010055896 polyornithine Proteins 0.000 description 1
- 229920002714 polyornithine Polymers 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 231100000955 reconstructed human epidermis model Toxicity 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- 210000005084 renal tissue Anatomy 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 210000004116 schwann cell Anatomy 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 210000000434 stratum corneum Anatomy 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 239000012581 transferrin Substances 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
- C12M25/00—Means for supporting, enclosing or fixing the microorganisms, e.g. immunocoatings
- C12M25/14—Scaffolds; Matrices
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
- C12M21/00—Bioreactors or fermenters specially adapted for specific uses
- C12M21/08—Bioreactors or fermenters specially adapted for specific uses for producing artificial tissue or for ex-vivo cultivation of tissue
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
- C12M25/00—Means for supporting, enclosing or fixing the microorganisms, e.g. immunocoatings
- C12M25/02—Membranes; Filters
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/0068—General culture methods using substrates
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
- G01N33/5029—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on cell motility
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5047—Cells of the immune system
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5082—Supracellular entities, e.g. tissue, organisms
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
- C12M23/00—Constructional details, e.g. recesses, hinges
- C12M23/02—Form or structure of the vessel
- C12M23/12—Well or multiwell plates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2535/00—Supports or coatings for cell culture characterised by topography
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/70—Mechanisms involved in disease identification
- G01N2800/7095—Inflammation
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Cell Biology (AREA)
- Urology & Nephrology (AREA)
- Genetics & Genomics (AREA)
- Hematology (AREA)
- General Engineering & Computer Science (AREA)
- Sustainable Development (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Medicinal Chemistry (AREA)
- Food Science & Technology (AREA)
- Toxicology (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Description
- 再構築された組織モデルを得るように培養細胞の支持及び栄養摂取を可能にする、小さなサイズだが高密度の多孔性と、
- 1つの区画から別の区画へのいくつかの細胞型の循環及び細胞質突起の通過を可能にする、大きなサイズだが低密度の多孔性と
の2種類の多孔性を含む膜の製造が可能であることを示した。
(i)膜1cm2当たり細孔1×105〜1×108個の密度で0.1から1μmの間の平均直径を有する細孔と、
(ii)膜1cm2当たり細孔0.5×102〜5×103個の密度で2から12の間の平均直径を有する細孔と
を含み、2種類の細孔が、膜の厚さを一方の面から反対側まで貫通している、単層膜を目的とする。
(i)膜1cm2当たり細孔1×106〜8.5×107個の密度で0.4μmの平均直径を有する細孔と、
(ii)膜1cm2当たり細孔2.5×102〜1×103個の密度、好ましくは膜1cm2当たり2.5×102、5×102、又は1×103の密度で、2から12μmの間、好ましくは5μmの平均直径を有する細孔と
を含み、2種類の細孔が、膜の厚さを一方の面から反対側まで貫通しており、同じ方向を向いている、単層膜である。
(a)膜1cm2当たり細孔1×105〜1×108個の密度で0.1から1μmの間の平均直径を有する細孔を含む細胞培養のための単層膜を準備する工程と、
(b)膜1cm2当たり細孔0.5×102〜5×103個の密度で2から12μmの間の平均直径を有する細孔を生成するように前記膜を穿孔する工程と
を含む。
A) 壁部のうちの少なくとも1つが膜1cm2当たり細孔1×105〜1×108個の密度で0.1から1μmの間の平均直径を有する細孔を含む単層膜を含むか又はそれによって構成されている少なくとも1つの区画を含む細胞培養デバイスを準備する工程と、
B) 膜1cm2当たり細孔0.5×102〜5×103個の密度で2から12μmの間の平均直径を有する細孔を生成するように前記膜を穿孔する工程と
を含む。
- 本明細書上記に定義された少なくとも1つの第1の細胞型を含む細胞群(i)と、
- 少なくとも1つの第2の細胞型を含む細胞群(ii)と
を含み、細胞群(i)及び(ii)は、本発明による膜によって分離されている。
a)培養デバイスの区画に、再構築される組織の第1の細胞型を、培養デバイスの膜にそれが接着することを可能にするように播種する工程と、
b)組織の特徴的な細胞構成を可能にするのに好適な期間及び条件で、細胞を培養下に維持する工程と
を含む方法も目的とする。
a1)培養デバイスの区画に、再構築される組織の第1の細胞型を播種する工程と、
a2)培養デバイスの膜への細胞の接着を可能にするために必要な期間の後、第2の細胞型を播種する工程と、
b)組織の特徴的な細胞構成を可能にするのに好適な期間及び条件で、細胞を培養下に維持する工程と
を含む。
a) 本発明による再構築された生体組織において免疫細胞の活性化及び遊走を伴う炎症反応を示す、この再構築された生体組織の存在下に、スクリーニングされる薬剤を置く工程と、
b) 再構築された生体組織内の免疫細胞の活性化及び遊走の、起こりうる変化を判定する工程と、
c) 工程b)において変化が判定された場合、スクリーニングされる薬剤が、免疫細胞の活性化及び遊走を伴う、組織、特に上皮の炎症反応を調節する可能性が高い薬剤であることを、そこから推定する工程と
を含むインビトロ法も目的とする。
a) 少なくとも1つの第1の細胞型を含む細胞群(i)と、神経細胞を含む細胞群(ii)とを含む(ここで、細胞群(i)及び(ii)は、細胞群(i)に対する細胞群(ii)の神経細胞の細胞質突起の通過を可能にする、本発明による膜によって分離されている)、本発明による再構築された生体組織の存在下に、スクリーニングされる薬剤を置く工程と、
b) 再構築された生体組織内の神経細胞の活性の、起こりうる変化を、神経細胞内及び/又は神経細胞による物質Pの放出の電気的活動を測定することによって判定する工程と、
c) 工程b)において変化が判定された場合、スクリーニングされる薬剤が、組織内に存在する神経終末と相互作用することによって、組織、特に上皮の感覚反応を調節する可能性が高い薬剤であることを、そこから推定する工程と
を含むインビトロ法も目的とする。
本発明による膜及びインサートの製造
本発明者らは、細胞培養及び組織再構築に使用されている市場の産業的インサートを使用して2つ以上の異なる細孔直径を有するシステムを製造することが可能であることを示した。
本発明による膜上の組織の再構築
ヒト上皮モデルを再構築するための従来の技術を使用し、本発明者らは、実施例1の膜上に、標準的なRHE skinethicモデルの特徴と同等な形態学的特徴(組織学)及び機能的特徴(細胞生存能、バリア機能)を有する、再構築されたヒト表皮(RHE)を再構築した(図2)。
Claims (13)
- 少なくとも2種類の細孔を含む細胞培養のための単層膜であって、
(i)膜1cm2当たり細孔1×105〜1×108個の密度で0.1から1μmの間の平均直径を有する細孔と、
(ii)膜1cm2当たり細孔0.5×102〜5×103個の密度で2から12μmの間の平均直径を有する細孔と
を含み、2種類の細孔が、膜の厚さを一方の面から反対側まで貫通している、単層膜。 - 2種類の細孔が同じ方向を向いている、請求項1に記載の単層膜。
- 前記膜がポリカーボネート膜である、請求項1又は2に記載の単層膜。
- 請求項1から3のいずれか一項に記載の膜を製造する方法であって、膜1cm2当たり細孔1×105〜1×108個の密度で0.1から1μmの間の平均直径を有する細孔を含む細胞培養のための単層膜を、膜1cm2当たり細孔0.5×102〜5×103個の密度で2から12μmの間の平均直径を有する細孔を生成するように穿孔することからなる工程を含む方法。
- 膜がレーザー穿孔によって穿孔される、請求項4に記載の製造方法。
- 壁部のうちの少なくとも1つが請求項1から3のいずれか一項に記載の膜を含むか又はそれによって構成されている少なくとも1つの区画を含む細胞培養デバイス。
- 前記デバイスが、2つの区画を含み、前記壁部が、2つの区画を分離する前記膜を含むか又はそれによって構成されている、請求項6に記載のデバイス。
- 請求項6又は7に記載の細胞培養デバイスを製造する方法であって、壁部のうちの少なくとも1つが膜1cm2当たり細孔1×105〜1×108個の密度で0.1から1μmの間の平均直径を有する細孔を含む膜を含むか又はそれによって構成されている少なくとも1つの区画を含む、細胞培養のための単層膜を、膜1cm2当たり細孔0.5×102〜5×103個の密度で2から12μmの間の平均直径を有する細孔を生成するように穿孔することからなる工程を含む方法。
- 細胞培養のための、請求項1から3のいずれか一項に記載の膜又は請求項6若しくは7に記載のデバイスのインビトロ使用。
- 再構築された生体組織の調製のための、請求項1から3のいずれか一項に記載の膜又は請求項6若しくは7に記載のデバイスの使用。
- 請求項1から3のいずれか一項に記載の膜上に、少なくとも1つの第1の細胞型を含む少なくとも1つの細胞群(i)を含む、再構築された生体組織。
- 請求項6又は7に記載の細胞培養デバイスにおいて、少なくとも1つの細胞型を含む再構築された生体組織を調製する方法であって、
a)培養デバイスの区画に、再構築される組織の第1の細胞型を、培養デバイスの膜にそれが接着することを可能にするように播種する工程と、
b)組織の特徴的な細胞構成を可能にするのに好適な期間及び条件で、細胞を培養下に維持する工程と
を含む方法。 - 免疫細胞の活性化及び遊走を伴う組織の炎症反応を調節する可能性が高い薬剤をスクリーニングするため、又は組織内に存在する神経終末と相互作用することによって組織の感覚反応を調節する可能性が高い薬剤をスクリーニングするための、請求項11に記載の再構築された生体組織の使用。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR1562707 | 2015-12-17 | ||
FR1562707A FR3045664A1 (fr) | 2015-12-17 | 2015-12-17 | Membrane pour tissu reconstruit comprenant des pores de plusieurs diametres |
PCT/EP2016/081797 WO2017103279A1 (en) | 2015-12-17 | 2016-12-19 | Membrane for reconstructed tissue comprising pores of several diameters |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2018537116A JP2018537116A (ja) | 2018-12-20 |
JP6698844B2 true JP6698844B2 (ja) | 2020-05-27 |
Family
ID=55236794
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2018531519A Active JP6698844B2 (ja) | 2015-12-17 | 2016-12-19 | いくつかの直径の細孔を含む再構築された組織のための膜 |
Country Status (7)
Country | Link |
---|---|
US (1) | US10920184B2 (ja) |
EP (1) | EP3390615B1 (ja) |
JP (1) | JP6698844B2 (ja) |
CN (1) | CN108473930B (ja) |
BR (1) | BR112018012223B1 (ja) |
FR (1) | FR3045664A1 (ja) |
WO (1) | WO2017103279A1 (ja) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113694749A (zh) * | 2020-05-21 | 2021-11-26 | 杭州科百特科技有限公司 | 一种大小混合孔径聚合物滤膜及其制备方法以及用途 |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080044637A1 (en) * | 2004-01-23 | 2008-02-21 | Yasuhito Masuda | Microhole-Formed Stretched Porous Polytetrafluoroethylene Material and Production Process Thereof, and Abrasion Working Process |
JP2007525667A (ja) | 2004-02-17 | 2007-09-06 | ヘンケル カーゲーアーアー | マイクロ流体分析用デバイス |
ATE495238T1 (de) * | 2005-12-21 | 2011-01-15 | Vaxdesign Corp | Iin vitro methode um eine potentielle reaktion eines tieres an einen agenten zu bestimmen |
FR2895748B1 (fr) | 2006-01-05 | 2008-04-04 | Oreal | Modele de culture cellulaire et ses applications |
CA2641733C (en) * | 2006-02-10 | 2015-03-31 | Tengion, Inc. | Scaffolds for organ reconstruction and augmentation |
EP2082030A2 (en) * | 2006-10-20 | 2009-07-29 | Keracure, Inc. | Devices with cells cultured on flexible supports |
JP5579620B2 (ja) | 2008-01-10 | 2014-08-27 | ヒューレル コーポレーション | 免疫システムモデリング・デバイスおよび方法 |
EP2394670A1 (en) * | 2010-06-04 | 2011-12-14 | Université de Liège | Chitosan-based biomimetic scaffolds and methods for preparing the same |
US8673628B2 (en) * | 2011-06-10 | 2014-03-18 | Essen Instruments, Inc. | Methods and apparatus for improving in vitro measurements using boyden chambers |
US9200246B2 (en) * | 2011-12-01 | 2015-12-01 | Acea Biosciences, Inc. | Co-culture device assembly |
US20140243354A1 (en) * | 2013-02-22 | 2014-08-28 | Galderma Research & Development Snc | Combinations of indigo naturalis and berberine and uses thereof |
CN104211981A (zh) * | 2014-09-11 | 2014-12-17 | 北京航空航天大学 | 一种多级蜂窝状微孔聚合物薄膜自组装成形的方法 |
JP6612979B2 (ja) | 2015-10-28 | 2019-11-27 | チャイナ ウェイファー レベル シーエスピー カンパニー リミテッド | イメージセンシングチップのパッケージ構造とパッケージング方法 |
-
2015
- 2015-12-17 FR FR1562707A patent/FR3045664A1/fr active Pending
-
2016
- 2016-12-19 US US16/061,139 patent/US10920184B2/en active Active
- 2016-12-19 JP JP2018531519A patent/JP6698844B2/ja active Active
- 2016-12-19 CN CN201680074504.5A patent/CN108473930B/zh active Active
- 2016-12-19 WO PCT/EP2016/081797 patent/WO2017103279A1/en active Application Filing
- 2016-12-19 BR BR112018012223-8A patent/BR112018012223B1/pt active IP Right Grant
- 2016-12-19 EP EP16823259.3A patent/EP3390615B1/en active Active
Also Published As
Publication number | Publication date |
---|---|
US20180362912A1 (en) | 2018-12-20 |
BR112018012223B1 (pt) | 2022-05-24 |
WO2017103279A1 (en) | 2017-06-22 |
BR112018012223A2 (pt) | 2018-11-27 |
CN108473930A (zh) | 2018-08-31 |
EP3390615A1 (en) | 2018-10-24 |
JP2018537116A (ja) | 2018-12-20 |
CN108473930B (zh) | 2022-04-01 |
US10920184B2 (en) | 2021-02-16 |
EP3390615B1 (en) | 2020-02-26 |
FR3045664A1 (fr) | 2017-06-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7227211B2 (ja) | 人工三次元皮膚組織、そのアレイ、およびその製造方法 | |
Shamir et al. | Three-dimensional organotypic culture: experimental models of mammalian biology and disease | |
EP3208328A1 (en) | Tissue fragment | |
WO2012133629A1 (ja) | 人工皮膚モデルの製造方法、及び人工皮膚モデル | |
JP2005027598A (ja) | 細胞培養チップ及び培養器、それらを用いた細胞培養方法、球状細胞組織体を担持させた細胞担持モジュール、球状細胞組織体 | |
JP2016093149A (ja) | 細胞培養装置および細胞培養方法 | |
JP7316745B2 (ja) | 三次元組織体 | |
US20180371390A1 (en) | A cell culture device | |
JP6835384B1 (ja) | 細胞培養装置及びその使用 | |
EP3077499A1 (en) | Fluidic device and perfusion system for in vitro complex living tissue reconstruction | |
US20220228108A1 (en) | Cell culture base material and cell culture base material with cells | |
JP6698844B2 (ja) | いくつかの直径の細孔を含む再構築された組織のための膜 | |
EP3187580A1 (en) | Artificial peritoneal tissue and method for producing same | |
EP3733831A1 (en) | Artificial tissue perfusion device and method of drug assessment using artificial tissue | |
Romo‐Morales et al. | Alvetex®, a highly porous polystyrene scaffold for routine three‐dimensional cell culture | |
JP5920749B2 (ja) | 人工皮膚モデルの製造方法、及び人工皮膚モデル | |
US20230287318A1 (en) | Methods for producing mature adipocytes and methods of use thereof | |
EP4363549A1 (en) | Stackable plates for culturing tissue models | |
JP2023035224A (ja) | 管状皮膚培養物 | |
EP3725872A1 (en) | Cell encapsulation device with suction tube and use thereof | |
JP6315604B2 (ja) | 人工皮膚モデルの製造方法、及び人工皮膚モデル | |
CN117957303A (zh) | 细胞培养装置、使用该细胞培养装置的细胞培养方法、包括该细胞培养装置的细胞培养孵箱以及该细胞培养装置的用途 | |
Tedesco et al. | 3D engineered neural networks coupled to Micro-Electrode based devices: a new experimental model for neurophysiological applications | |
TW202115237A (zh) | 肝細胞培養體之製造方法、含細胞之多孔膜及肝細胞或肝前驅細胞的功能提高或功能維持方法 | |
del Veneto | 3D MICROFABRICATED SCAFFOLDS AND MICROFLUIDIC DEVICES FOR OCULAR SURFACE REPLACEMENT: A |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20180802 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20190617 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20190619 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20190912 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20200330 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20200428 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6698844 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |